<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800462</url>
  </required_header>
  <id_info>
    <org_study_id>2007-SCI-M3-488</org_study_id>
    <nct_id>NCT00800462</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity</brief_title>
  <official_title>Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toronto Rehabilitation Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Neurotrauma Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Toronto Rehabilitation Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and&#xD;
      safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with&#xD;
      one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals&#xD;
      with spinal cord injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Incontinence Episodes</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event Reporting</measure>
    <time_frame>Each Study Visit and Follow-up Phone Call</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urodynamic Study</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Neurogenic Detrusor Overactivity</condition>
  <arm_group>
    <arm_group_label>Oxybutynin Cl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trospium Cl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Darifenacin Hydrogren Bromide (HBr)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin Cl</intervention_name>
    <description>15 mg qd for 3 months</description>
    <arm_group_label>Oxybutynin Cl</arm_group_label>
    <other_name>Uromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trospium Cl</intervention_name>
    <description>20mg bid for 3 months</description>
    <arm_group_label>Trospium Cl</arm_group_label>
    <other_name>Trosec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darifenacin Hydrogen Bromide (HBr)</intervention_name>
    <description>15 mg qd for 3 months</description>
    <arm_group_label>Darifenacin Hydrogren Bromide (HBr)</arm_group_label>
    <other_name>Enablex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients, between 18 and 75 years of age. Female patients of&#xD;
             childbearing potential* must have a negative urine pregnancy test result on the day of&#xD;
             Screening Visit and practice a reliable method of contraception**&#xD;
&#xD;
             *A female is considered of childbearing potential unless she is:&#xD;
&#xD;
               -  Postmenopausal for at least 12 months prior to study drug administration;&#xD;
&#xD;
               -  Without a uterus and/or both ovaries; or&#xD;
&#xD;
               -  Has been surgically sterilized for at least 6 months prior to study drug&#xD;
                  administration.&#xD;
&#xD;
                  **Reliable methods of contraception include:&#xD;
&#xD;
               -  Hormonal methods or intrauterine device in use at least 30 days prior to study&#xD;
                  drug administration;&#xD;
&#xD;
               -  Barrier methods plus spermicidal in use at least 14 days prior to study drug&#xD;
                  administration; or&#xD;
&#xD;
               -  Sexual abstinence as a lifestyle.&#xD;
&#xD;
          2. Patients with a neurogenic bladder and detrusor overactivity secondary to a spinal&#xD;
             cord injury.&#xD;
&#xD;
               -  Patients with urinary incontinence (minimum of one occurrence per day) despite&#xD;
                  current treatment. [NOTE: Bladder emptying may be accomplished with straining,&#xD;
                  intermittent catheterization (IC), spontaneous micturition or leakage episodes.]&#xD;
&#xD;
          3. Patients with serum creatinine within normal limits and normal renal function&#xD;
&#xD;
          4. Patients on a stable dose (minimum one month) of concomitant medication for Neurogenic&#xD;
             detrusor overactivity&#xD;
&#xD;
          5. Patients must have adequate cognitive function to understand the requirements of the&#xD;
             study, including completing questionnaires and signing a written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female patients who are pregnant (positive urine pregnancy test), planning to become&#xD;
             pregnant during the study period, breast-feeding, or who are of childbearing potential&#xD;
             and not practicing a reliable method of birth control.&#xD;
&#xD;
          2. Patients with a history of transurethral sphincterotomy, bladder neck or prostatic&#xD;
             resection, previous bladder surgery including myomectomy or augmentation cystoplasty.&#xD;
&#xD;
          3. Patients with chronic indwelling catheters.&#xD;
&#xD;
          4. Patients with, in the opinion of the Investigator, unstable or stable multiple&#xD;
             sclerosis.&#xD;
&#xD;
          5. Patients with known, uncontrolled systemic disease.&#xD;
&#xD;
          6. Patients with evidence of recent alcohol/drug abuse.&#xD;
&#xD;
          7. Patients with urinary retention, gastrointestinal obstructive disorders or&#xD;
             uncontrolled narrow-angle glaucoma.&#xD;
&#xD;
          8. Patients with contraindications to Trosec™, Enablex™ and Uromax®.&#xD;
&#xD;
          9. Patients who, in the opinion of the Investigator, have a significant condition or&#xD;
             situation that may put the patient at significant risk, confound the study results, or&#xD;
             interfere significantly with the patient's participation in the study.&#xD;
&#xD;
         10. Patients with a history of poor cooperation, non-compliance, or unreliability.&#xD;
&#xD;
         11. Patients currently participating in an investigational drug study or who have&#xD;
             participated in an investigational drug study within 30 days of the Screening Visit.&#xD;
&#xD;
         12. Patients administered anticholinergics and/or antispasmodic drugs during the course of&#xD;
             the study.&#xD;
&#xD;
         13. Patient with hepatic insufficiency.&#xD;
&#xD;
         14. Patient has been administered intravesical botulinum toxin within 6 months prior to&#xD;
             the Screening Visit and/or is expected to receive intravesical botulinum toxin during&#xD;
             the course of the study.&#xD;
&#xD;
         15. Patient has any medical condition that would interfere with the interpretation of the&#xD;
             study results or the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy Hassouna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto Rehabilitation Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Manitoba, Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Rehabilitation Institute, Lyndhurst Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.onf.org</url>
    <description>Ontario Neurotrauma Foundation</description>
  </link>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Toronto Rehabilitation Institute</investigator_affiliation>
    <investigator_full_name>Magdy Hassouna</investigator_full_name>
    <investigator_title>MD PhD FRCSC FACS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Darifenacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

